|
CA1247080A
(en)
|
1983-03-08 |
1988-12-20 |
Commonwealth Serum Laboratories Commission |
Antigenically active amino acid sequences
|
|
US5906936A
(en)
*
|
1988-05-04 |
1999-05-25 |
Yeda Research And Development Co. Ltd. |
Endowing lymphocytes with antibody specificity
|
|
IL86278A
(en)
|
1988-05-04 |
2003-06-24 |
Yeda Res & Dev |
Endowing cells with antibody specificity using chimeric t cell receptor
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5199942A
(en)
|
1991-06-07 |
1993-04-06 |
Immunex Corporation |
Method for improving autologous transplantation
|
|
US8211422B2
(en)
|
1992-03-18 |
2012-07-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric receptor genes and cells transformed therewith
|
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
|
EP1958962A3
(en)
|
1997-06-12 |
2013-05-01 |
Novartis International Pharmaceutical Ltd. |
Artificial antibody polypeptides
|
|
TWI224995B
(en)
|
1998-03-19 |
2004-12-11 |
Ciba Sc Holding Ag |
Stabilization of wood substrates
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
PL207087B1
(pl)
|
2001-04-26 |
2010-10-29 |
Biogen |
Przeciwciało, które wiąże się swoiście z białkiem Cripto, zawierająca je kompozycja farmaceutyczna i zastosowanie przeciwciała
|
|
IL160359A0
(en)
|
2001-08-31 |
2004-07-25 |
Avidex Ltd |
Soluble t cell receptor
|
|
EP1427377A4
(en)
|
2001-09-20 |
2006-04-12 |
Cornell Res Foundation Inc |
METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING SKIN DISORDERS USING SPECIFIC BINDING AGENTS FOR A PROSTATE-SPECIFIC MEMBRANE ANTIGEN
|
|
CA2467242A1
(en)
|
2001-11-20 |
2003-05-30 |
Seattle Genetics, Inc. |
Treatment of immunological disorders using anti-cd30 antibodies
|
|
US6992176B2
(en)
|
2002-02-13 |
2006-01-31 |
Technion Research & Development Foundation Ltd. |
Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
|
|
AU2003216341A1
(en)
|
2002-02-20 |
2003-09-09 |
Dyax Corporation |
Mhc-peptide complex binding ligands
|
|
CA2501870C
(en)
*
|
2002-10-09 |
2013-07-02 |
Avidex Limited |
Single chain recombinant t cell receptors
|
|
GB0304068D0
(en)
*
|
2003-02-22 |
2003-03-26 |
Avidex Ltd |
Substances
|
|
CU23403A1
(es)
|
2003-04-23 |
2009-08-04 |
Centro Inmunologia Molecular |
Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
|
|
US7709610B2
(en)
|
2003-05-08 |
2010-05-04 |
Facet Biotech Corporation |
Therapeutic use of anti-CS1 antibodies
|
|
AR044388A1
(es)
|
2003-05-20 |
2005-09-07 |
Applied Molecular Evolution |
Moleculas de union a cd20
|
|
AU2005246073B2
(en)
*
|
2004-05-19 |
2010-10-28 |
Adaptimmune Limited |
Method of improving T cell receptors
|
|
ATE417065T1
(de)
|
2004-05-19 |
2008-12-15 |
Medigene Ltd |
Hochaffiner ny-eso-t-zellen-rezeptor
|
|
WO2005118788A2
(en)
*
|
2004-05-27 |
2005-12-15 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
ES2382627T3
(es)
|
2004-06-29 |
2012-06-12 |
B.R.A.H.M.S Gmbh |
Nuevos anticuerpos monoclonales estimuladores o bloqueadores de la tiroides, secuencias peptídicas que corresponden a sus regiones variables, y sus usos en medicina diagnóstica, preventiva y terapéutica
|
|
JP2008516586A
(ja)
|
2004-09-30 |
2008-05-22 |
メダレックス インコーポレーティッド |
Ｆｃγ受容体ＩＩ（ＣＤ３２）に対するヒトモノクローナル抗体
|
|
JP2008514685A
(ja)
*
|
2004-10-01 |
2008-05-08 |
メディジーン リミテッド |
治療剤に連結した、非天然型ジスルフィド鎖間結合を含有するｔ細胞レセプター
|
|
DE602005022928D1
(de)
|
2004-11-30 |
2010-09-23 |
Abgenix Inc |
Antikörper gegen gpnmb und ihre verwendungen
|
|
EP1838736B1
(en)
|
2005-01-05 |
2013-03-06 |
Biogen Idec MA Inc. |
Cripto binding molecules
|
|
DOP2006000029A
(es)
|
2005-02-07 |
2006-08-15 |
Genentech Inc |
Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
|
|
CA2611814A1
(en)
|
2005-06-20 |
2007-01-04 |
Medarex, Inc. |
Cd19 antibodies and their uses
|
|
EA017812B1
(ru)
|
2005-12-08 |
2013-03-29 |
Медарекс, Инк. |
Выделенное моноклональное антитело или его антигенсвязывающий участок, которые связываются с протеинтирозинкиназой 7 ( ptk7) человека, и их применение
|
|
US8383118B2
(en)
|
2005-12-08 |
2013-02-26 |
Medarex, Inc. |
Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1
|
|
ES2365046T3
(es)
|
2005-12-30 |
2011-09-21 |
Merck Patent Gmbh |
Anticuerpos anti-cd19 con inmunogenicidad reducida.
|
|
US20080131428A1
(en)
|
2006-02-24 |
2008-06-05 |
Arius Research, Inc. |
Cytotoxicity mediation of cells evidencing surface expression of TROP-2
|
|
EP1999148B8
(en)
|
2006-03-06 |
2014-03-05 |
Medlmmune, LLC |
Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
EP2032606B1
(en)
|
2006-05-30 |
2013-11-27 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
|
RU2495882C2
(ru)
|
2006-09-08 |
2013-10-20 |
Медиммун, Ллк. |
Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания
|
|
BRPI0807571A2
(pt)
|
2007-02-22 |
2014-07-01 |
Othera Holding Inc |
Compostos de hidroxilamina e métodos de seu uso
|
|
EP2014302A1
(en)
|
2007-07-12 |
2009-01-14 |
Institut Curie |
An antibody specific for the Tn antigen for the treatment of cancer
|
|
EP2186825A1
(en)
*
|
2008-11-13 |
2010-05-19 |
Max-Delbrück-Centrum für Molekulare Medizin (MDC) |
Human-derived T cell receptors
|
|
UA109633C2
(uk)
|
2008-12-09 |
2015-09-25 |
|
Антитіло людини проти тканинного фактора
|
|
KR20110128876A
(ko)
|
2009-02-16 |
2011-11-30 |
바이오렉스 쎄라퓨틱스, 인코포레이티드 |
인간화된 항-ｃｄ20 항체 및 이용 방법
|
|
CN102421800A
(zh)
|
2009-02-23 |
2012-04-18 |
格兰马克药品股份有限公司 |
结合cd19的人源化抗体及其用途
|
|
WO2010107658A2
(en)
|
2009-03-16 |
2010-09-23 |
Vallera Daniel A |
Methods and compositions for bi-specific targeting of cd19/cd22
|
|
DK2421898T3
(en)
|
2009-04-20 |
2016-05-30 |
Oxford Biotherapeutics Ltd |
Cadherin-17 SPECIFIC ANTIBODIES
|
|
US8318162B2
(en)
|
2009-07-16 |
2012-11-27 |
Xoma Technology Ltd. |
Antibodies to high molecular weight melanoma associated antigen
|
|
SG10201407757XA
(en)
|
2009-10-23 |
2015-01-29 |
Millennium Pharm Inc |
Anti-gcc antibody molecules and related compositions and methods
|
|
WO2011059836A2
(en)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
T cell receptor-deficient t cell compositions
|
|
US20120269814A1
(en)
|
2009-11-10 |
2012-10-25 |
Amgen Inc. |
Anti-c mpl antibodies
|
|
CA3255551A1
(en)
|
2010-03-26 |
2025-04-15 |
Memorial Sloan-Kettering Cancer Center |
MUC16 ANTIBODIES AND METHODS OF USE
|
|
EP3165533B1
(en)
|
2010-05-11 |
2020-04-08 |
Fred Hutchinson Cancer Research Center |
Chlorotoxin variants, conjugates and methods for their use
|
|
EP2571901B1
(en)
|
2010-05-20 |
2019-01-02 |
Ablynx N.V. |
Biological materials related to her3
|
|
EP2409993A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC function with improved glycosylation profile
|
|
US9163258B2
(en)
|
2010-07-23 |
2015-10-20 |
Fred Hutchinson Cancer Research Center |
Method for the treatment of obesity
|
|
AR082641A1
(es)
|
2010-09-07 |
2012-12-19 |
Imclone Llc |
Composiciones de anticuerpo anti-vegfr-3
|
|
EP2621953B1
(en)
|
2010-09-30 |
2017-04-05 |
Ablynx N.V. |
Biological materials related to c-met
|
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
|
MX2013004792A
(es)
|
2010-10-27 |
2013-08-27 |
Baylor College Medicine |
Receptor cd27 quimericos para redirigir celulas t a malignidades cd70-positivas.
|
|
MX2013011363A
(es)
|
2011-04-01 |
2014-04-25 |
Sloan Kettering Inst Cancer |
Anticuerpos para peptidos citosolicos.
|
|
KR101972446B1
(ko)
|
2011-05-27 |
2019-04-25 |
글락소 그룹 리미티드 |
Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）결합 단백질
|
|
WO2012170785A1
(en)
|
2011-06-08 |
2012-12-13 |
The Regents Of The University Of California |
Anti-cd22 antigen binding molecules to treat lung cancer and prostate cancer
|
|
WO2013019730A1
(en)
|
2011-07-29 |
2013-02-07 |
The Washington University |
Antibodies to tip-1 and grp78
|
|
KR20140064873A
(ko)
|
2011-08-16 |
2014-05-28 |
모르포시스 아게 |
항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
|
|
PT2768942T
(pt)
|
2011-10-17 |
2020-01-21 |
Massachusetts Inst Technology |
Entrega intracelular
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
US20130302274A1
(en)
|
2011-11-25 |
2013-11-14 |
Roche Glycart Ag |
Combination therapy
|
|
BR112014020826A8
(pt)
|
2012-02-24 |
2017-09-19 |
Stem Centrx Inc |
Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado
|
|
US9376485B2
(en)
|
2012-02-29 |
2016-06-28 |
The Brigham And Women's Hospital, Inc. |
Neutralizing antibody for epstein barr virus-associated disease
|
|
MX2014010987A
(es)
|
2012-03-12 |
2015-03-03 |
Medimmune Llc |
Tratamiento de esclerosis multiple con anticuerpo anti-cd19.
|
|
US9163090B2
(en)
|
2012-05-07 |
2015-10-20 |
Cellerant Therapeutics, Inc. |
Antibodies specific for CLL-1
|
|
WO2013167153A1
(en)
|
2012-05-09 |
2013-11-14 |
Ganymed Pharmaceuticals Ag |
Antibodies useful in cancer diagnosis
|
|
US20130309223A1
(en)
|
2012-05-18 |
2013-11-21 |
Seattle Genetics, Inc. |
CD33 Antibodies And Use Of Same To Treat Cancer
|
|
BR112014029417B1
(pt)
|
2012-05-25 |
2023-03-07 |
Cellectis |
Método ex vivo para a preparação de células t para imunoterapia
|
|
WO2014039513A2
(en)
|
2012-09-04 |
2014-03-13 |
The Trustees Of The University Of Pennsylvania |
Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
|
|
CN104955845B
(zh)
|
2012-09-27 |
2018-11-16 |
美国政府(由卫生和人类服务部的部长所代表) |
间皮素抗体和引起有效的抗肿瘤活性的方法
|
|
US9695228B2
(en)
|
2012-11-21 |
2017-07-04 |
Janssen Biotech, Inc. |
EGFR and c-Met fibronectin type III domain binding molecules
|
|
EP2738180A1
(en)
|
2012-11-30 |
2014-06-04 |
Molecular Partners AG |
Binding proteins comprising at least two binding domains against HER2.
|
|
US9803021B2
(en)
|
2012-12-07 |
2017-10-31 |
The Regents Of The University Of California |
CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
|
|
HK1210713A1
(en)
|
2012-12-27 |
2016-05-06 |
Sanofi |
Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
|
|
EP2948478B1
(en)
|
2013-01-25 |
2019-04-03 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
|
CN113684185A
(zh)
|
2013-02-26 |
2021-11-23 |
纪念斯隆-凯特琳癌症中心 |
用于免疫疗法的组合物和方法
|
|
CA2904236A1
(en)
|
2013-03-05 |
2014-09-12 |
Baylor College Of Medicine |
Heparanase expression in t lymphocytes
|
|
ES2671004T3
(es)
|
2013-03-07 |
2018-06-04 |
Baylor College Of Medicine |
Dirección a CD138 en cáncer
|
|
EP2970312B1
(en)
|
2013-03-11 |
2017-11-15 |
The Regents of The University of Michigan |
Bet bromodomain inhibitors and therapeutic methods using the same
|
|
EP2970492B1
(en)
|
2013-03-15 |
2019-05-08 |
Wake Forest University Health Sciences |
Antibodies against human and canine il-13ra2
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
US9790282B2
(en)
|
2013-03-25 |
2017-10-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
|
|
CN104140974B
(zh)
|
2013-05-08 |
2017-09-29 |
科济生物医药（上海）有限公司 |
编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
|
|
EP3783098A1
(en)
|
2013-05-14 |
2021-02-24 |
Board Of Regents, The University Of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
|
CA2913052A1
(en)
|
2013-05-24 |
2014-11-27 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor-targeting monoclonal antibodies
|
|
ES2716867T3
(es)
|
2013-05-31 |
2019-06-17 |
Cellectis Sa |
Endonucleasa de asentamiento LAGLIDADG que escinde el gen de receptor de células T alfa y usos de la misma
|
|
GB201313377D0
(en)
|
2013-07-26 |
2013-09-11 |
Adaptimmune Ltd |
T cell receptors
|
|
EP3027755B1
(en)
|
2013-08-02 |
2019-10-09 |
The Regents of The University of California |
Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
|
|
EP2840091A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
|
|
EP2839842A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
|
|
GB201317929D0
(en)
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
CN105814083A
(zh)
|
2013-10-15 |
2016-07-27 |
加州生物医学研究所 |
嵌合抗原受体t细胞开关和其用途
|
|
US10144770B2
(en)
|
2013-10-17 |
2018-12-04 |
National University Of Singapore |
Chimeric receptors and uses thereof in immune therapy
|
|
EP3074419B1
(en)
|
2013-11-25 |
2018-08-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors to control hiv infection
|
|
WO2015080981A1
(en)
|
2013-11-27 |
2015-06-04 |
Baylor College Of Medicine |
Csgp4-specific chimeric antigen receptor for cancer
|
|
SG11201604784XA
(en)
|
2013-12-13 |
2016-07-28 |
Genentech Inc |
Anti-cd33 antibodies and immunoconjugates
|
|
US10214584B2
(en)
|
2014-01-15 |
2019-02-26 |
Order-Made Medical Research Inc. |
Therapeutic pharmaceutical composition employing anti-SLC6A6 antibody
|
|
WO2015112626A1
(en)
|
2014-01-21 |
2015-07-30 |
June Carl H |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
|
WO2015120180A1
(en)
|
2014-02-05 |
2015-08-13 |
The University Of Chicago |
Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants
|
|
DK3241561T3
(da)
|
2014-03-05 |
2025-06-30 |
Autolus Ltd |
Konjugeret antistof eller bispecifik t-celle-engager, som selektivt binder enten tcr-beta konstant region 1 (trbc1) eller trbc2
|
|
GB201403875D0
(en)
|
2014-03-05 |
2014-04-16 |
Cantargia Ab |
Novel antibodies and uses thereof
|
|
US20170335281A1
(en)
|
2014-03-15 |
2017-11-23 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
PT3514172T
(pt)
|
2014-04-01 |
2020-04-21 |
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh |
Imunorrecetores específicos de claudina-6 e epítopos de células t
|
|
GB201406767D0
(en)
|
2014-04-15 |
2014-05-28 |
Cancer Rec Tech Ltd |
Humanized anti-Tn-MUC1 antibodies anf their conjugates
|
|
PL3134432T3
(pl)
|
2014-04-25 |
2020-10-19 |
Bluebird Bio, Inc. |
Promotor mnd chimeryczne receptory antygenowe
|
|
CN113604491A
(zh)
|
2014-05-02 |
2021-11-05 |
宾夕法尼亚大学董事会 |
嵌合自身抗体受体t细胞的组合物和方法
|
|
EP2944652A1
(en)
|
2014-05-13 |
2015-11-18 |
Technische Universität München |
Glypican-3-specific T-cell receptors and their uses for immunotherapy of hepatocellular carcinoma
|
|
MX375379B
(es)
*
|
2014-05-29 |
2025-03-06 |
Us Health |
Receptores de celulas t anti - papilomavirus 16 e7 humano.
|
|
US9212225B1
(en)
|
2014-07-01 |
2015-12-15 |
Amphivena Therapeutics, Inc. |
Bispecific CD33 and CD3 binding proteins
|
|
TWI719942B
(zh)
|
2014-07-21 |
2021-03-01 |
瑞士商諾華公司 |
使用ｃｄ３３嵌合抗原受體治療癌症
|
|
BR112017001183A2
(pt)
|
2014-07-21 |
2017-11-28 |
Novartis Ag |
tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
|
|
UY36245A
(es)
|
2014-07-31 |
2016-01-29 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
|
ES2841274T3
(es)
|
2014-08-04 |
2021-07-07 |
Hutchinson Fred Cancer Res |
Inmunoterapia con células T específica para WT-1
|
|
MA40513A
(fr)
|
2014-08-12 |
2017-06-21 |
Novartis Ag |
Conjugués médicament-anticorps anti-cdh6
|
|
AU2015301460B2
(en)
|
2014-08-14 |
2021-04-08 |
Novartis Ag |
Treatment of cancer using GFR alpha-4 chimeric antigen receptor
|
|
KR102387122B1
(ko)
|
2014-08-19 |
2022-04-14 |
밀테니 비오텍 비.브이. & 씨오. 케이지 |
Ssea4 항원에 특이적인 키메라 항원 수용체
|
|
EP2990416B1
(en)
|
2014-08-29 |
2018-06-20 |
GEMoaB Monoclonals GmbH |
Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
|
|
US10093746B2
(en)
|
2014-09-04 |
2018-10-09 |
The Trustees Of The University Of Pennsylvania |
Glypican-3 antibody and uses thereof
|
|
MA40609B1
(fr)
|
2014-09-05 |
2020-05-29 |
Janssen Pharmaceutica Nv |
Agents de liaison cd123 et leurs utilisations
|
|
CA2972714A1
(en)
|
2014-09-09 |
2016-03-17 |
Unum Therapeutics |
Chimeric receptors and uses thereof in immune therapy
|
|
MA40579A
(fr)
|
2014-09-12 |
2016-03-17 |
Genentech Inc |
Anticorps anti-cll-1 et immunoconjugués
|
|
JP2017529841A
(ja)
|
2014-09-19 |
2017-10-12 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
キメラ抗原受容体
|
|
JP2017529851A
(ja)
|
2014-09-26 |
2017-10-12 |
ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ |
養子免疫療法のためのグリピカン−３特異的キメラ抗原レセプター
|
|
AU2015339012B2
(en)
|
2014-10-31 |
2020-11-05 |
Abbvie Biotherapeutics Inc. |
Anti-CS1 antibodies and antibody drug conjugates
|
|
EP3212774A4
(en)
*
|
2014-10-31 |
2018-04-11 |
Baylor College of Medicine |
Survivin specific t-cell receptor targeting tumor but not t cells
|
|
KR102614189B1
(ko)
|
2014-11-17 |
2023-12-18 |
리제너론 파아마슈티컬스, 인크. |
Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법
|
|
CN118271463A
(zh)
|
2014-12-05 |
2024-07-02 |
纪念斯隆-凯特琳癌症中心 |
靶向g-蛋白偶联受体的嵌合抗原受体及其用途
|
|
SI3226897T1
(sl)
|
2014-12-05 |
2021-08-31 |
Memorial Sloan Kettering Cancer Center |
Protitelesa, ki ciljajo na B-celični maturacijski antigen, in postopki uporabe
|
|
BR112017011932A8
(pt)
|
2014-12-05 |
2022-11-08 |
Memorial Sloan Kettering Cancer Center |
Anticorpos direcionados a receptor acoplado a proteína g e métodos de uso
|
|
HRP20191873T1
(hr)
|
2014-12-12 |
2020-01-24 |
Bluebird Bio, Inc. |
Kimerni antigenski receptori
|
|
PL3560953T3
(pl)
|
2014-12-24 |
2024-05-13 |
Autolus Limited |
Komórka
|
|
CN120988137A
(zh)
|
2015-01-23 |
2025-11-21 |
赛诺菲 |
抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
|
|
BR112017013981A2
(pt)
|
2015-01-26 |
2018-01-02 |
Cellectis |
receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
|
|
EP3253793A4
(en)
|
2015-02-02 |
2018-11-14 |
i2 Pharmaceuticals, Inc. |
Anti-surrogate light chain antibodies
|
|
WO2016154047A2
(en)
|
2015-03-20 |
2016-09-29 |
Memorial Sloan-Kettering Cancer Center |
Monoclonal antigen-binding proteins to intracellular oncogene products
|
|
AU2016243583B2
(en)
|
2015-03-27 |
2022-03-10 |
President And Fellows Of Harvard College |
Modified T cells and methods of making and using the same
|
|
WO2016160618A2
(en)
|
2015-03-27 |
2016-10-06 |
University Of Southern California |
Car t-cell therapy directed to lhr for the treatment of solid tumors
|
|
US10294304B2
(en)
|
2015-04-13 |
2019-05-21 |
Pfizer Inc. |
Chimeric antigen receptors targeting B-cell maturation antigen
|
|
AU2016249005B2
(en)
|
2015-04-17 |
2022-06-16 |
Novartis Ag |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
EP3288568A4
(en)
|
2015-04-30 |
2019-01-02 |
University of Southern California |
Secretory tnt car cell immunotherapy
|
|
US10844111B2
(en)
|
2015-05-06 |
2020-11-24 |
Janssen Biotech, Inc. |
Prostate specific membrane antigen binding fibronectin type III domains
|
|
LT3611192T
(lt)
|
2015-05-13 |
2025-06-25 |
Ablynx N.V. |
T ląstelių rekrutingo polipeptidai tcr alfa/beta reaktyvumo pagrindu
|
|
PL3298033T5
(pl)
*
|
2015-05-18 |
2023-10-30 |
TCR2 Therapeutics Inc. |
Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
|
|
US9422547B1
(en)
*
|
2015-06-09 |
2016-08-23 |
Gigagen, Inc. |
Recombinant fusion proteins and libraries from immune cell repertoires
|
|
AU2016274767B2
(en)
|
2015-06-09 |
2022-05-19 |
Eureka Therapeutics, Inc. |
T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA
|
|
CN108348551A
(zh)
|
2015-08-28 |
2018-07-31 |
宾夕法尼亚大学董事会 |
表达嵌合细胞内信号传导分子的细胞的方法和组合物
|
|
AU2016323985B2
(en)
|
2015-09-17 |
2022-12-15 |
Novartis Ag |
CAR T cell therapies with enhanced efficacy
|
|
IL302560B2
(en)
|
2015-10-13 |
2025-08-01 |
Hope City |
Chimeric antigen receptors containing a chlorotoxin domain
|
|
MX2018004721A
(es)
*
|
2015-10-23 |
2018-07-06 |
Eureka Therapeutics Inc |
Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
|
|
EA201891084A1
(ru)
|
2015-11-02 |
2019-10-31 |
|
Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение
|
|
US11768203B2
(en)
|
2016-03-31 |
2023-09-26 |
University Of Southern California |
Highly sensitive and specific luciferase based reporter assay for antigen detection
|
|
ES2891578T3
(es)
|
2016-04-01 |
2022-01-28 |
Kite Pharma Inc |
Antígeno quimérico y receptores de células T y métodos de uso
|
|
TWI795133B
(zh)
|
2016-04-01 |
2023-03-01 |
美商凱特製藥公司 |
Ｂｃｍａ結合分子類及彼等之用途
|
|
US12060394B2
(en)
|
2016-04-28 |
2024-08-13 |
The Trustees Of Dartmouth College |
Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
|
|
WO2017192536A1
(en)
*
|
2016-05-02 |
2017-11-09 |
University Of Kansas |
Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
|
|
CA3030603A1
(en)
|
2016-07-14 |
2018-01-18 |
University Of Southern California |
Methods and composition for producing and using immune cells and stem cells for cell-based therapies
|
|
RU2019104074A
(ru)
|
2016-07-15 |
2020-08-18 |
Посейда Терапьютикс, Инк. |
Химерные рецепторы антигенов и способы их применения
|
|
EP4596707A3
(en)
|
2016-09-19 |
2025-10-08 |
University of Southern California |
Non-radioactive cytotoxicity assays
|
|
GB2595980B
(en)
|
2019-01-04 |
2023-06-14 |
Marengo Therapeutics Inc |
Anti-TCR antibody molecules and uses thereof
|